Group 1 - The company has approved a share buyback plan to reduce its registered capital by repurchasing shares through centralized bidding, with a total fund of no less than RMB 50 million and no more than RMB 100 million, at a price not exceeding RMB 6.95 per share [2][35] - As of November 14, 2025, the company repurchased a total of 8,000,000 shares, reducing the total number of shares from 700,000,046 to 692,000,046, and consequently decreasing the registered capital from RMB 700,000,046 to RMB 692,000,046 [3][7] - The company has revised its articles of association to reflect the reduction in registered capital, with no other changes to the remaining content [4][7] Group 2 - The company has agreed to sell 62% of its subsidiary, Taiyuan Pharmaceutical Co., Ltd., to Shanxi Tongxiang Times Technology Co., Ltd. for RMB 87,188,740, resulting in the company retaining only 5% of the subsidiary's shares [9][12] - The transaction is aimed at optimizing the company's asset structure and resource allocation, enhancing operational efficiency, and is expected to increase the company's profit by approximately RMB 59 million for the year 2025 [31] - The transaction does not constitute a related party transaction or a major asset restructuring, and it does not require shareholder approval [13][17]

Core Viewpoint - The company plans to sell 62% of its subsidiary, Taiyuan Pharmaceutical Co., Ltd., to Shanxi Tongxiang Times Technology Co., Ltd. for RMB 87.19 million, which will enhance asset operational efficiency and provide funding support for business expansion [1] Group 1: Transaction Details - The transaction price for the 62% stake in Taiyuan Pharmaceutical is RMB 87.19 million [1] - After the transaction, Shanxi Tongxiang will hold 95% of Taiyuan Pharmaceutical, while the company will retain a 5% stake [1] - Taiyuan Pharmaceutical will no longer be included in the company's consolidated financial statements post-transaction [1] Group 2: Strategic Rationale - The transaction is based on comprehensive considerations for the company's future development [1] - It aims to improve asset operational efficiency and reduce management costs [1] - The company anticipates an increase in profit of approximately RMB 59 million for the year 2025 following the completion of the transaction (unaudited) [1]

Group 1: Financing and Investment Plans - Shengyi Electronics plans to raise no more than 2.6 billion yuan through a private placement to invest in AI computing HDI production base, smart manufacturing high-layer circuit board projects, and to supplement working capital and repay bank loans [2] - Lianmicro intends to invest 2.262 billion yuan to construct a project with an annual production capacity of 1.8 million pieces of 12-inch heavily doped substrate wafers [3] - Daimei Co. plans to invest 100 million yuan to establish a wholly-owned subsidiary focused on robotics technology [5] Group 2: Stock Performance and Trading - Furi Shares experienced a significant stock price fluctuation, with an 8-day cumulative deviation of 113.94%, indicating potential irrational speculation [2] - Tianfu Communication has set the initial inquiry transfer price at 140 yuan per share, reflecting a 7.2% discount from the closing price [7] - Ningde Times' third-largest shareholder is transferring shares at a price of 376.12 yuan per share, with full subscription from 16 institutional investors [6] Group 3: Operational Updates - Yongtai Technology's wholly-owned subsidiary is set to begin trial production of a lithium battery additive project with an annual capacity of 5,000 tons, increasing the total capacity to 10,000 tons per year [3] - Trina Solar's subsidiary signed contracts for the sale of 2.66 GWh of energy storage products, which is expected to positively impact future operating performance [5] - Yinglian Co. signed a strategic procurement contract for over 50 million square meters of composite aluminum foil materials for quasi-solid-state batteries, which will enhance its operational development in 2026-2027 [5] Group 4: Corporate Restructuring and Management - Huaxia Happiness has been designated a temporary manager for pre-restructuring by the court, pending a decision on its restructuring application [8] - The National Integrated Circuit Fund has reduced its stake in Shengke Communication by 2.49%, completing its planned share reduction [4]

Core Viewpoint - The company plans to sell 62% of its subsidiary Taiyuan Pharmaceutical Co., Ltd. to Shanxi Tongxiang Times Technology Co., Ltd. for RMB 87.1887 million, which will result in a significant change in ownership structure and financial reporting [1][2] Group 1: Transaction Details - After the transaction, Shanxi Tongxiang will hold 95% of Taiyuan Pharmaceutical, while the company will retain 5%, leading to Taiyuan Pharmaceutical being excluded from the company's consolidated financial statements [1][2] - The transaction is based on an asset-based valuation method, with Taiyuan Pharmaceutical's net asset book value at RMB 54.1061 million and a total equity valuation of RMB 141 million, resulting in an appraisal increment of RMB 86.5209 million and an increase rate of 159.91% [1] Group 2: Financial Impact - The company anticipates that the transaction will increase its profit by approximately RMB 59 million for the fiscal year 2025, subject to final audited figures [1] - Taiyuan Pharmaceutical reported revenues of RMB 9.0671 million and RMB 390,400 for the years 2024 and January to August 2025, respectively, with net losses of RMB 15.3785 million and RMB 614,730 during the same periods [1] Group 3: Operational Changes - Employee placement at Taiyuan Pharmaceutical has been completed, and its management will be nominated by Shanxi Tongxiang after the transaction [2] - The company confirms that there are no guarantees or financial management arrangements involving Taiyuan Pharmaceutical, and there will be no related party transactions or competition issues post-transaction [2] Group 4: Company Performance - The company reported a third-quarter revenue of RMB 569 million, a year-on-year decrease of 16.01%, and a net profit of RMB 40.6971 million, down 26.22% [2] - For the first three quarters, the company achieved revenues of RMB 1.709 billion, a decline of 19.46%, and a net profit of RMB 215 million, down 8.44% [2]

Core Viewpoint - The company plans to sell 62% of its subsidiary, Taiyuan Pharmaceutical Co., Ltd., to Shanxi Tongxiang Times Technology Co., Ltd. for RMB 87.19 million, which will result in a significant change in ownership structure and financial reporting [1] Group 1: Transaction Details - The transaction price for the 62% stake in Taiyuan Pharmaceutical is RMB 87.19 million [1] - After the transaction, Shanxi Tongxiang will hold 95% of Taiyuan Pharmaceutical, while the company will retain a 5% stake [1] - Taiyuan Pharmaceutical will no longer be included in the company's consolidated financial statements following the completion of the transaction [1] Group 2: Strategic Rationale - The transaction is based on comprehensive considerations for the company's future development [1] - It aims to improve asset operational efficiency, reduce management costs, and enhance the company's ongoing operational capabilities [1] - The company anticipates that the transaction will provide financial support for business expansion, with an estimated increase in profit of approximately RMB 59 million for the year 2025 (unaudited) [1]

Core Viewpoint - The company plans to sell 62% of its subsidiary Taiyuan Pharmaceutical to Shanxi Tongxiang Times Technology for a transaction price of 87.1887 million yuan, which will enhance asset operation efficiency and provide funding support for business expansion [1] Group 1 - The transaction will result in Shanxi Tongxiang holding 95% of Taiyuan Pharmaceutical, while the company retains 5% [1] - Taiyuan Pharmaceutical will no longer be included in the company's consolidated financial statements after the transaction [1] - The company estimates that the transaction will increase its total profit by approximately 59 million yuan in 2025 [1]

Core Viewpoint - Yabao Pharmaceutical (SH 600351) announced the transfer of 62% equity in its subsidiary Taiyuan Pharmaceutical to Tongxiang Technology for approximately RMB 87.19 million, aiming to optimize asset structure and improve operational efficiency [1] Group 1: Company Actions - The equity transfer will result in Tongxiang Technology holding 95% of Taiyuan Pharmaceutical, while Yabao will retain 5%, leading to Taiyuan Pharmaceutical being excluded from Yabao's consolidated financial statements [1] - The transaction is part of Yabao's strategy to lower management costs and enhance asset operation efficiency [1] Group 2: Financial Performance - For the year 2024, Yabao Pharmaceutical's revenue composition is as follows: 75.46% from pharmaceutical manufacturing, 21.37% from pharmaceutical wholesale, 1.88% from other trading, and 1.29% from other businesses [1] - As of the report date, Yabao Pharmaceutical's market capitalization stands at RMB 4.8 billion [1]

Core Viewpoint - The company, Yabao Pharmaceutical, plans to sell 62% of its subsidiary, Taiyuan Pharmaceutical, to Shanxi Tongxiang Times Technology for a transaction price of 87.1887 million yuan, aiming to enhance operational efficiency and support future business expansion [1] Group 1: Transaction Details - The transaction involves the sale of 62% equity of Taiyuan Pharmaceutical to Tongxiang Technology for 87.1887 million yuan [1] - The company anticipates that the transaction will increase its total profit by approximately 59 million yuan in 2025, based on preliminary calculations [1] Group 2: Strategic Rationale - The sale is part of a comprehensive consideration for the company's future development, aimed at improving asset operation efficiency and reducing management costs [1] - The transaction is expected to enhance the company's ongoing operational capabilities and provide financial support for business expansion [1] Group 3: Employee and Management Changes - Employee placement at Taiyuan Pharmaceutical has been completed prior to the transaction [1] - Post-transaction, the management of Taiyuan Pharmaceutical will be nominated by Tongxiang Technology [1]

亚宝药业集团股份有限公司 章 程 （2025年11月修订） 目 录 1 第一章 总则 第二章 经营宗旨和范围 第三章 股份 第一节 股份发行 第二节 股份增减和回购 第三节 股份转让 第四章 股东和股东会 第一节 股东 第二节 控股股东和实际控制人 第三节 股东会的一般规定 第四节 股东会的召集 第五节 股东会的提案与通知 第六节 股东会的召开 第七节 股东会的表决和决议 第五章 董事和董事会 第一节 董事的一般规定 第二节 董事会 第三节 独立董事 第六章 高级管理人员 第七章 财务会计制度、利润分配和审计 第一节 财务会计制度 第二节 内部审计 第三节 会计师事务所的聘任 第八章 通知与公告 第一节 通知 第二节 公告 第九章 合并、分立、增资、减资、解散和清算 第一节 合并、分立、增资和减资 第二节 解散和清算 第十章 修改章程 第十一章 附则 第一章 总 则 第一条 为维护亚宝药业集团股份有限公司（以下简称"公司"）、股东、 职工和债权人的合法权益，规范公司的组织和行为，根据《中华人民共和国公司 法》（以下简称《公司法》）、《中华人民共和国证券法》（以下简称《证券法》） 和其他有关规定，制订本章程。 ...

证券代码：600351 证券简称：亚宝药业 公告编号：2025-047 1 交易简要内容：亚宝药业集团股份有限公司（以下简称"亚宝药业"或"公 司"）拟将控股子公司亚宝药业太原制药有限公司（以下简称"太原制药" 或"目标公司"）62%的股权出售给山西同享时代科技有限公司（以下简 称"同享科技"），交易价格为人民币 87,188,740 元（以下简称"本次交易"）。 本次交易完成后，同享科技持有太原制药 95%的股权，公司持有太原制 药 5%的股权，太原制药将不再纳入公司合并报表范围内。 本次交易不构成关联交易。 本次交易不构成重大资产重组。 本次交易无需提交股东会审议。 截止本公告日，公司不存在为太原制药提供担保、委托其理财的情形， 太原制药亦不存在占用公司资金的情形。 本次股权转让事项尚需相关方按照协议约定支付转让款并办理标的股 权过户手续方为完成，本次交易对方具备履约能力及付款能力，但依然 存在不能按协议约定及时支付股权转让对价的履约风险，交易最终能否 成功实施尚存在不确定性。敬请广大投资者理性投资，注意投资风险。 制药将不再纳入公司合并报表范围内。 （二）公司于 2025 年 11 月 17 日召开了第 ...